Theratechnologies Resumes Distribution of EGRIFTA SV®
EGRIFTA SV® is distributed in the United States only.
Wane1d
Viking Psychiatry: Spravato Approved as a Monotherapy
Living Local 15 host Jessica Williams is joined by Sean Goddard, a Psychiatric Nurse Practitioner and Owner of Viking Psychiatry, to speak about the recent approval for Spravato as a monotherapy ...
pharmaphorum6d
J&J builds case for antidepressant Spravato with head-to-head trial
Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.
pharmaphorum3d
J&J’s Spravato for depression ‘should be much cheaper’
Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...
Medscape1d
Duloxetine in the Treatment of Major Depressive Disorder: An Open-Label Study
Background: Major depressive disorder (MDD) is a chronic and highly disabling condition. Existing pharmacotherapies produce full remission in only 30% to 40% of treated patients. Antidepressants ...
Pharm Exec2d
All News
The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for refractory systemic lupus erythematosus with extrarenal involvement, marking the ...